Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosu...
Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II
About this item
Full title
Author / Creator
Publisher
United States: American Thoracic Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Thoracic Society
Subjects
More information
Scope and Contents
Contents
The Scleroderma Lung Study II (SLS II) demonstrated significant improvements in pulmonary function and dyspnea at 24 months compared with baseline when patients with symptomatic scleroderma-related interstitial lung disease (SSc-ILD) were treated with either cyclophosphamide for 1 year (followed for another year on placebo) or mycophenolate mofetil...
Alternative Titles
Full title
Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6322015
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6322015
Other Identifiers
ISSN
2329-6933
E-ISSN
2325-6621
DOI
10.1513/AnnalsATS.201802-079OC
